Selank Shows Immunomodulatory Effects in Patients with Anxiety and Depression
Background
Many individuals suffer from anxiety-asthenic disorders and depression, often accompanied by immune system dysregulation, where the body's immune response is imbalanced. While existing treatments target neurological symptoms, there's a significant knowledge gap regarding how novel neurotrophic peptides like Selank might influence the immune system in these patient populations.
Results
In vitro experiments revealed that Selank at 10-7 M completely suppressed the gene expression of IL-6 (Interleukin-6, a pro-inflammatory cytokine) in peripheral blood cells from depressed patients, but not in healthy controls. Intriguingly, at the same time, a significant increase (p<0.05) in IL-6 protein concentration was observed in the cell culture of peripheral blood from patients in the presence of Selank. In patients with generalized anxiety disorder and neurasthenia treated with Selank for 14 days, significant changes were observed in the Th1/Th2 (T helper 1/T helper 2, key immune cell subsets) cytokine balance in their serum, showing a significant inverse correlation with clinical improvement.
Why It Matters
These findings suggest that Selank possesses unique immunomodulatory properties, acting as a novel regulator of the immune response. This dual effect on IL-6 gene expression and protein concentration, alongside its impact on Th1/Th2 balance, highlights its potential beyond direct neurological effects. This could lead to Selank being used as an innovative immunomodulator for patients with anxiety-asthenic disorders, potentially offering adaptogenic benefits for elderly individuals or those exposed to environmental stressors to prevent infectious diseases. Further research, including larger human trials (e.g., Phase II/III), is needed to confirm these effects and establish optimal dosing.